Erasca Positions Itself Proactively Against Hard-to-Treat Tumors

Erasca is a biopharmaceutical company based in the USA that focuses on the development of novel cancer medications, specifically addressing signaling pathways that play a central role in many types of tumors. The strategic focus is on targeted therapies against the RAS MAPK signaling pathway, which is considered one of the most important yet challenging targets in oncology. Erasca is taking a precision medicine approach and developing multiple drug candidates in parallel to target different points within the same biological network. The aim is to...